Akili, Inc. (NASDAQ:AKLI) Sees Significant Drop in Short Interest

Akili, Inc. (NASDAQ:AKLI) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 271,400 shares, a decline of 56.5% from the May 31st total of 623,800 shares. Based on an average daily volume of 1,960,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the company’s shares are sold short.

Akili Stock Down 1.0 %

NASDAQ AKLI traded down $0.00 on Friday, reaching $0.43. The company had a trading volume of 14,743 shares, compared to its average volume of 2,220,044. Akili has a 52 week low of $0.19 and a 52 week high of $1.25. The stock’s 50 day moving average is $0.40 and its 200-day moving average is $0.35. The company has a current ratio of 5.80, a quick ratio of 5.80 and a debt-to-equity ratio of 0.08.

Akili (NASDAQ:AKLI) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.38 million during the quarter. Akili had a negative net margin of 2,492.04% and a negative return on equity of 79.93%. As a group, analysts predict that Akili will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of Akili

A hedge fund recently raised its stake in Akili stock. Longitude Cayman Ltd. lifted its holdings in shares of Akili, Inc. (NASDAQ:AKLI) by 75.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 350,000 shares of the company’s stock after purchasing an additional 150,000 shares during the quarter. Longitude Cayman Ltd. owned 0.45% of Akili worth $102,000 at the end of the most recent quarter. Institutional investors own 53.12% of the company’s stock.

Akili Company Profile

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.